Molbio Diagnostics IPO - GMP, Subscription, Price, Dates & Financial Details
Molbio Diagnostics IPO is set to open its Initial Public Offering (IPO) for subscription on August 10, 2026. According to the Red Herring Prospectus (RHP), the IPO is a book-built issue with a total issue size of ₹0 Crore and an offer for sale (OFS) of 91.66 Lakh equity shares aggregating to ₹0.00 Crore by the existing shareholders.
The Molbio Diagnostics IPO will open for subscription on August 10, 2026, and close on August 12, 2026. The basis of allotment is expected to be finalized on August 13, 2026, while the shares are tentatively scheduled to be listed on the NSE and BSE on August 17, 2026.
The price band and lot size for Molbio Diagnostics IPO are yet to be announced.
KFin Technologies Limited is the registrar to the issue. IIFL Capital Services Limited, Jefferies India Private Limited, Kotak Mahindra Capital Company Limited, and Motilal Oswal Investment Advisors Ltd are the Book Running Lead Managers (BRLMs) to the issue.
Before investing in the Molbio Diagnostics IPO, investors should carefully review the company's financial performance, business model, IPO objectives, and risk factors disclosed in the offer documents. Investors should also ensure that they submit their applications before the subscription window closes on August 12, 2026.
- Issue Price
- Yet to Be Announced
- Lot Size
- Not Announced
- Issue Size
- Not Announced
- Minimum Investment
- Not Announced
- Listing Date
- 17 August 2026
Current GMP
₹0
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
About Molbio Diagnostics Limited
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of innovative rapid diagnostic solutions for infectious and non-communicable diseases.
The company has developed its proprietary Truenat platform, a portable, battery-operated, PCR-based molecular diagnostics system specifically designed for resource-limited settings. The platform delivers highly accurate molecular test results within approximately one hour, enabling timely diagnosis and treatment at the point of care.
Molbio offers a comprehensive portfolio of molecular diagnostic solutions covering more than 30 diseases through 43 diagnostic assays. Its product portfolio includes tests for tuberculosis (TB), COVID-19, HIV, Hepatitis B, Hepatitis C, Human Papillomavirus (HPV), and several other infectious diseases. In addition to molecular diagnostics, the company provides advanced healthcare solutions in radiology, digital pathology, and breast health screening through its subsidiaries and strategic partnerships. Molbio continues to strengthen its product pipeline through significant investments in in-house research and development.
The company operates six state-of-the-art manufacturing facilities across India and serves customers in more than 90 countries. Its diverse customer base includes government healthcare programs, public and private hospitals, diagnostic laboratories, research institutions, and international healthcare organizations. Supported by a robust intellectual property portfolio, global quality certifications, and strategic acquisitions, Molbio has established itself as a leading innovator in the molecular diagnostics industry.
As of March 31, 2026, Molbio Diagnostics Limited employed 1,225 permanent employees across various functions, including research and development, manufacturing, quality assurance, regulatory affairs, sales and marketing, finance, information technology, and corporate operations.
Molbio Diagnostics IPO Promoters
- Chandrasekhar Bhaskaran Nair
- Exxora Trading LLP
- Sangeetha Sriram
- Shiva Sriram
- Sowmya Sriram
- Sriram Natarajan
Promoters Holding
Holding Pre Issue
46.65%
Holding Post Issue
0.00%
Molbio Diagnostics IPO Objective
The Company Molbio Diagnostics IPO proposes to utilise the Net Proceeds from the Issue towards the following objects.
- Funding capital expenditure towards the setting up of infrastructure for our research and development facility, Center of Excellence and connected office space
- Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit
- General corporate purposes
Molbio Diagnostics Limited Address / Contact Details
Molbio Diagnostics Limited
Plot No. L-46
Phase II-D, Verna Industrial Area
Verna, Salcete South Goa, Goa, 403722
Telephone: +91 832 672488
Email: investors@molbiodiagnostics.com
Website: https://www.molbiodiagnostics.com/
IPO Snapshot
Book Running Lead Managers
- IIFL Capital Services Limited
- Jefferies India Private Limited
- Kotak Mahindra Capital Company Limited
- Motilal Oswal Investment Advisors Ltd
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
What is the Molbio Diagnostics IPO?
Molbio Diagnostics IPO is a Book-building IPO with a total issue size of ₹0 crore. The Molbio Diagnostics IPO price band is ₹0 to 0 per share. The Molbio Diagnostics IPO subscription opens on Mon, Aug 10, 2026, and closes on Wed, Aug 12, 2026. The Molbio Diagnostics IPO will be listed on the BSE,NSE. KFin Technologies Limited is the registrar for the Molbio Diagnostics IPO.
When will the Molbio Diagnostics IPO open for subscription?
The Molbio Diagnostics IPO opens on Mon, Aug 10, 2026 and closes on Wed, Aug 12, 2026
What is Molbio Diagnostics IPO Price Band?
Molbio Diagnostics IPO Price Band is ₹0 to 0 per share.
What is Molbio Diagnostics IPO Lot Size?
Molbio Diagnostics IPO lot size is 0 shares, Retail investors need a minimum investment of ₹0 based on the upper price band
What is the minimum investment for Molbio Diagnostics IPO?
The minimum investment for Molbio Diagnostics IPO is ₹0, based on one lot of 0 shares at the upper price band of ₹0 per share.
How to apply for Molbio Diagnostics IPO?
Investors can apply for the Molbio Diagnostics IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Wed, Aug 12, 2026. The application amount remains blocked until the Molbio Diagnostics IPO allotment is finalized.
What is Molbio Diagnostics IPO Issue Size?
Molbio Diagnostics IPO issue size is ₹0 crores.
What is the Molbio Diagnostics IPO Allotment Date?
Molbio Diagnostics IPO allotment date is Thu, Aug 13, 2026.
Who is the Molbio Diagnostics IPO Registrar?
The registrar for Molbio Diagnostics IPO is KFin Technologies Limited. Investors can go to KFin Technologies Limited website to check Molbio Diagnostics IPO allotment status, refund processing, and other IPO-related information.
Who is the Molbio Diagnostics IPO Lead Manager?
The book-running lead managers (BRLMs) for the Molbio Diagnostics IPO are Jefferies India Private Limited, Kotak Mahindra Capital Company Limited, and Motilal Oswal Investment Advisors Ltd. The lead managers are responsible for managing the IPO process, including issue structuring, regulatory compliance, marketing the public issue, coordinating with investors, and ensuring a smooth listing process. For complete details, investors should refer to the Molbio Diagnostics IPO Red Herring Prospectus (RHP).